Literature DB >> 8863352

An outbreak of mumps in a population partially vaccinated with the Rubini strain.

D Germann1, A Ströhle, K Eggenberger, C A Steiner, L Matter.   

Abstract

Since 1991, 6 years after the recommendation of universal childhood triple vaccination against measles, mumps and rubella (M + M + R), Switzerland has been confronted with an increasing number of mumps cases affecting both vaccinated and unvaccinated children. The M + M + R vaccine mainly used in the Swiss population after 1986 contains the highly attenuated Rubini strain of mumps virus. We analysed an outbreak of 102 suspected mumps cases by virus isolation, determination of IgM antibodies to mumps virus in 27 acute phase sera, and verification of vaccination histories. Mumps was confirmed by virus isolation in 88 patients, of whom 72 had previously received the Rubini vaccine strain. IgM antibodies to mumps virus were detected in 24/27 acute phase serum samples. A group of 92 subjects from the same geographic area without signs of mumps virus infection served as controls. IgG antibodies to mumps virus and vaccination status were assessed in these children. The vaccination rate in these controls was 61%, with equal seropositivity for unvaccinated and Rubini-vaccinated subjects. These data support other recent reports which indicate an insufficient protective efficacy of current mumps vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863352     DOI: 10.3109/00365549609027163

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  15 in total

1.  Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study.

Authors:  M Schlegel; J J Osterwalder; R L Galeazzi; P L Vernazza
Journal:  BMJ       Date:  1999-08-07

2.  Mumps: a current epidemiologic pattern as a necessary background for the choice of a vaccination strategy.

Authors:  C Zotti; O Ossola; R Barberis; A Castella; A M Ruggenini
Journal:  Eur J Epidemiol       Date:  1999-08       Impact factor: 8.082

3.  Re: V. Usonis et al.: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (Infection 26 [1998] 222-226)

Authors:  D Nalin
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

4.  Molecular identification of mumps virus genotypes from clinical samples: standardized method of analysis.

Authors:  G Palacios; O Jabado; D Cisterna; F de Ory; N Renwick; J E Echevarria; A Castellanos; M Mosquera; M C Freire; R H Campos; W I Lipkin
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

5.  Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.

Authors:  L Matter; D Germann; F Bally; K Schopfer
Journal:  Eur J Epidemiol       Date:  1997-01       Impact factor: 8.082

6.  Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases.

Authors:  G P Poggio; C Rodriguez; D Cisterna; M C Freire; J Cello
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

7.  [Mumps in a urban area of the Community of Madrid. Vaccination status, diagnosis and intervention measures].

Authors:  R de los Ríos Martín; N García Marín; J Sanz Moreno; E Ballester Orcal
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

8.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

9.  Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.

Authors:  C Amela; I Pachón; F de Ory
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G.

Authors:  M Narita; Y Matsuzono; Y Takekoshi; S Yamada; O Itakura; M Kubota; H Kikuta; T Togashi
Journal:  Clin Diagn Lab Immunol       Date:  1998-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.